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PROGNOSIS OF PRIMARY THYROID LYMPHOMA: DEMOGRAPHIC, CLINICAL 
AND PATHOLOGIC PREDICTORS OF SURVIVAL 
Amanda Graff-Baker, Sanziana A. Roman, Daniel C. Thomas, Robert Udelsman, Julie Ann Sosa, Section 
of Endocrine Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT 
The aim of this study is to assess associations between demographic, clinical and 
pathologic characteristics of patients with primary thyroid lymphoma (PTL) and survival, 
using both bivariate and multivariate analyses.  We hypothesize that age, stage at 
diagnosis, and histology will be independent predictors of survival after diagnosis of 
PTL.  Use of surgery to treat PTL will not improve survival. 
PTL patients were identified in the SEER database. Bivariate (χ
2
, Kaplan-Meier, 
and log rank) and multivariate (Cox proportional hazards) analyses were used to assess 
the associations between patient characteristics and survival. 
A total of 1,408 patients were identified.  Overall, 98% had non-Hodgkin‟s 
lymphoma; 68% had diffuse large B-cell, 10% follicular, 10% marginal zone, and 3% 
small lymphocytic. A total of 88% had stage I or II disease. Median survival was 9.3 
years. On bivariate analysis, older age, single marital status, stage II-IV disease, histology 
(diffuse large B-cell, follicular, or other non-Hodgkin‟s), earlier year of diagnosis, lack of 
prior malignancies, and no radiation or surgery predicted worse survival. Age ≥80 years, 
stage IV disease, no radiation or surgery, and large B-cell or follicular histology predicted 
worse prognosis in multivariate analysis.  
Based on the analysis, we conclude that older age, advanced stage, histologic 
subtype, and lack of radiation or surgical treatment are associated with worse survival. 
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Primary thyroid lymphoma (PTL) is a rare type of thyroid cancer. It has an estimated 
incidence of 1-5% of thyroid malignancies and 2% of all extranodal lymphomas, with an 
annual incidence of two per million (1-4). The vast majority of patients are diagnosed 
with non-Hodgkin‟s lymphoma of B-cell origin; Hodgkin‟s lymphoma has been rarely 
reported.  A number of distinct histologic subtypes exist, each with unique diagnostic and 
prognostic characteristics.  Due to the rarity of this malignancy, the literature contains 
only case reports and single institutional series evaluating PTL.  This work represents the 
first population-based study of PTL in the United States to examine associations among 
patient demographic, pathologic, and clinical characteristics, including the extent of 
thyroid resection, and overall and disease-specific survival. 
Clinical presentation 
The largest study of PTL in the United States to date encompassed 108 patients; it 
found that PTL most commonly affects women (3:1 predominance) between the ages of 
50 and 80 years, with a peak incidence in the late sixties (5).  Patients typically present 
with a rapidly growing thyroid mass and may experience hoarseness, stridor, or, less 
commonly, dysphagia (6).  The rate of thyroid enlargement tends to be more rapid in 
those with PTL than in patients with other thyroid malignancies, with the exception of 
anaplastic thyroid carcinoma (7).  Patients may also present with “B symptoms”, such as 
fever, night sweats, weight loss, pruritus, or all of the above.  Patients with chronic 
lymphocytic thyroiditis (Hashimoto‟s thyroiditis) are at increased risk of developing 
PTL.  There is a particularly strong association between Hashimoto‟s thyroiditis and 
marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT), with 
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an estimated relative risk of 67 (8).  At least one-half of patients diagnosed with PTL 
have a clinical history of Hashimoto‟s thyroiditis, and an even larger number have either 
immunologic or pathologic evidence of the disease, with a reported rate as high as 94% in 
one study (5, 9, 10).  Nonetheless, most patients with Hashimoto‟s thyroiditis do not 
develop PTL.  Hashimoto‟s thyroiditis is strongly linked to human leukocyte antigen 
(HLA) haplotype in certain populations, but recent investigations have not found a 
similar HLA association for patients with PTL (11). 
Histologic subtypes 
Diffuse large B-cell lymphoma 
PTL can be classified by histologic subtype. The most common of these subtypes 
is diffuse large B-cell lymphoma (DLBCL), which accounts for approximately two-thirds 
of cases (5).  In some patients, DLBCL may arise from a preexisting MALT lymphoma, 
and a component of MALT lymphoma can be seen in one-third of patients with DLBCL 
(9). In terms of cellular immunophenotype, thyroid DLBCLs are CD20 positive, and the 
majority are B-cell lymphoma (Bcl)-6 positive. Approximately half are Bcl-2 positive; 
CD5, CD10, and CD23 are usually negative (9).   
The most aggressive of the histologic subtypes, DLBCL is associated with the 
worst prognosis and is an independent predictor of death from PTL (5).  Positive 
cytoplasmic staining for nm23-H1 protein and the nongerminal center B-cell type are 
associated with a poor prognosis (9). 
Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue 
The second most common form of PTL, MALT is an indolent, low-grade 
malignancy.  Diagnostic features of thyroid MALT include lymphoepithelial lesions 
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(LEL), reactivation germinal centers, and frequent plasmacytic differentiation.  The 
utility of LELs as a diagnostic feature of extranodal MALT lymphoma has been 
questioned due to the presence of LELs in other histologic subtypes, but a recent site-
specific analysis reveals that LELs are found in 100% of thyroid MALT, indicating that 
their presence is important for diagnosis (12). The presence of immunoglobulin light 
chain, CD20, and Bcl-2 are expected, as are the absence of CD5, CD10, and CD23 (13). 
Histologic similarities between thyroid MALT and follicular lymphoma and the 
frequent association with Hashimoto‟s thyroiditis present diagnostic challenges (12, 14). 
Distinguishing MALT from plasma cell neoplasms can be accomplished with expanded 
immunostaining panels; immunoglobulin-M heavy chain staining in the plasma cell 
component strongly supports the diagnosis of MALT (12). Prominent plasma cell 
differentiation, follicular colonization, and presence of LELs may be found in 
Hashimoto‟s thyroiditis and PTL, but the diagnosis of MALT can be made on the basis of 
the presence of centrocyte-like cells on immunohistochemistry and clonal band on PCR 
for the immunoglobulin heavy chain (14). 
Multiple series that evaluated the histologic subtypes of PTL have reported that 
patients with MALT have longer disease-specific survival than those with DLBCL, 
although these disparities have not achieved statistical significance in all studies (5, 6, 15)  
MALT more frequently presents in stage I than DLBCL (15).  MALT patients respond 
well to treatment and are significantly more likely to achieve complete remission when 




Thyroid follicular lymphoma is widely reported to be less common than MALT.  
Due to its rarity, the clinicopathologic features of thyroid follicular lymphoma have only 
recently been characterized (16).  Thyroid follicular lymphomas have neoplastic follicles 
with typical follicular lymphoma morphology contained within a destructive atypical 
lymphoid infiltrate. The interfollicular cells are small centrocytic cells, and LELs are 
found in all cases. Immunohistochemistry commonly shows expression of Bcl-6, CD10 
or both within the interfollicular cells.  Bcl-2-positive thyroid follicular lymphoma is 
associated with disseminated disease, whereas Bcl-2-negative neoplasms are more likely 
to be localized. Follicular lymphoma can be distinguished from MALT by the expression 
of Bcl-6, the presence of areas with typical follicular lymphoma architecture, and the lack 
of immunoglobulin heavy chain expression (16). 
Other 
A number of other histologic subtypes of PTL have been reported, all at very low 
rates. Hodgkin‟s lymphoma, small lymphocytic lymphoma, and plasmacytoma each 
represent less than 5% of PTL, whereas T-cell, mantle cell, Burkitt‟s, and lymphoblastic 
histologies are found in less than 1% of cases (3, 17-19) 
Pathogenesis 
Theories describing the molecular pathogenesis of PTL have been based on the 
association between Hashimoto‟s thyroiditis and PTL. It has been postulated that the 
chronic antigenic stimulation and proliferation of lymphoid tissue in Hashimoto‟s 
thyroiditis creates cells that are susceptible to neoplastic transformation, leading to PTL. 
Recent work by Moshynska et al. (20) supports this theory, by showing clonal similarity 
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in immunoglobulin heavy chain gene rearrangement sequences in the clonal bands of 
Hashimoto‟s thyroiditis and subsequently developed PTL. 
The theory of antigenic stimulation does not explain the pathogenesis of PTL 
entirely, as demonstrated by Takakuwa et al. (21). Aberrant somatic hypermutation, 
previously attributed to the development of multiple proto-oncogenes in other types of 
DLBCL, was shown in this study to target thyroid DLBCL, MALT, and particularly 
follicular lymphoma. Interestingly, the authors also found aberrant somatic 
hypermutation in two patients of Hashimoto‟s thyroiditis, leading to them to propose that 
aberrant somatic hypermutation may represent an early step in the process of thyroid 
lymphomagenesis in patients with Hashimoto‟s thyroiditis. 
Diagnosis 
Despite its rarity, PTL should always be considered in the differential diagnosis of 
rapidly growing goiter or thyroid nodules. Definitive diagnosis of PTL is not possible 
based on history, physical examination, thyroid function tests, or imaging alone due to 
the lack of specificity of any of these for lymphoproliferative disorders.  Tissue is 
necessary for confirmation. 
Fine needle aspiration 
Fine needle aspiration (FNA) biopsy is an excellent diagnostic test for thyroid 
disorders as it is minimally invasive and can be performed in the office. Unfortunately, 
the reported accuracy of FNA is not high enough to rely solely on this test for diagnosis.  
This is largely due to the histopathological similarities between PTL and Hashimoto‟s 
thyroiditis. The lack of marked nuclear atypia in PTL makes the cytological 
differentiation between the lymphoid infiltrate of Hashimoto‟s thyroiditis and lymphoma 
6 
 
difficult (14, 15, 22). Several series have reported accurate diagnosis of PTL using FNA 
in 60% of patients who were later proven to have the malignancy (15, 23).  Takano et al. 
(22) proposed a diagnostic method for non-Hodkin‟s PTL in which the detection of a 
monoclonal immunoglobin heavy chain gene in B cells is combined with aspiration 
biopsy-nucleic acid diagnosis (ABND).  ABND uses extracted nucleic acids from 
leftover cells found within the needle after FNA to allow for the detection of various 
malignancies using the relatively small number of cells available in the needle. This 
technique seems promising, but it has not yet shown high enough sensitivity or specificity 
to replace the current diagnostic techniques. 
Core needle and surgical biopsy 
Most patients with suspected PTL require either core needle or open surgical 
biopsy for histopathological confirmation, classification of histologic subtype, and 
chemotherapeutic treatment planning. In a small study of six patients, ultrasound-guided 
core needle biopsy was shown to be safe and accurate, suggesting that it may be 
considered a suitable alternative to open surgical biopsy (24).  Nonetheless, the more 
limited core biopsy specimen may not be representative of the entire tumor, particularly 
in the case of coexisting MALT and DLBCL histologies. Thus, there continues to be a 
role for surgical biopsy to ensure that aggressive histologies are not missed (14). 
Pretreatment evaluation 
A number of laboratory studies are useful in evaluating patients with PTL. In 
addition to obtaining standard serologic chemistries, serum lactate dehydrogenase and β2 
microglobulin levels may be checked, as they have prognostic implications for non-
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Hodgkin‟s lymphoma (25).  Thyroid function tests may also be useful due to the high 
incidence of hypothyroidism in patients with PTL. 
Staging 
 PTL is staged based on the Ann Arbor staging criteria (26), with up to 90% of 
patients presenting with early stage disease (5, 15).  Stage IE (extranodal) PTL is defined 
as lymphoma limited to the confines of the thyroid gland, stage IIE denotes spread 
beyond the thyroid to regional lymph nodes, stage IIIE involves lymph nodes on both 
sides of the diaphragm, and stage IVE indicates systemic dissemination.  Prognosis varies 
by stage at diagnosis; patients who present with higher stage disease far significantly 
worse than those presenting at earlier stages (5, 6).                        
Imaging 
Cervical ultrasound is a standard initial imaging study in patients with thyroid 
disease and masses.  PTL often presents as a pseudocystic, hypoechoic region that can be 
mistaken for a benign cyst on sonography (24).  Therefore, a clear diagnosis cannot be 
made on ultrasound alone.  However, the use of ultrasound is particularly valuable in 
guiding appropriate FNA or core needle biopsies.  Once the diagnosis of PTL has been 
established, imaging of the entire body is necessary in order to stage the patient 
accurately.  Computed tomography (CT) of the head, neck, chest, abdomen, and pelvis 
are commonly employed.  The clinical utility of fluorodeoxyglucose-PET (FDG-PET) 
scanning has been of recent interest (27).  In patients with DLBCL, FDG-PET appears to 
be a sensitive modality for assessing PTL and may lead to earlier identification of disease 
recurrence than CT scan surveillance (28).  FDG-PET scanning is potentially inaccurate 
in patients with Hashimoto‟s thyroiditis, in whom inflammation causes diffusely 
8 
 
increased thyroid uptake and false-positive results.  FDG-PET is also of limited clinical 
utility in patients with MALT because the low metabolic rate of the malignancy and the 
high rates of concurrent Hashimoto‟s thyroiditis lead to difficulty in detecting residual or 
recurrent disease. 
Treatment 
Appropriate treatment for patients with PTL depends on histologic subtype, as the 
tumor grade and the efficacy of each treatment modality vary by subtype. Thirty years 
ago, PTL was considered a surgical disease, but the introduction of effective 
chemotherapeutic regimens has significantly changed the treatment paradigm since then.  
Currently, chemotherapy or combined chemotherapy and locoregional radiation are the 
mainstay of treatment for most histologic subtypes.  A study of 50 patients evaluating 
surgical trends in the management of thyroid lymphoma found that fewer patients 
underwent thyroid resection for therapeutic purposes in the latter half of the 35-year 
study period and that surgical thyroid resection had no impact on disease-free survival 
(29). 
Localized treatment 
Regardless of histologic subtype, there is consensus that the role of locoregional 
treatments, such as surgical excision and radiation, is limited to patients with stage I or II 
disease.  MALT and follicular lymphomas tend to follow a more indolent course and are 
frequently treated locally with either surgical excision or radiotherapy. Thyroid resections 
can be difficult in patients with PTL due to the inflammatory nature of thyroiditis and 
possible extrathyroidal extension. Some patients may present with a solitary thyroid 
nodule, which is only diagnosed as PTL after surgical resection.  Anecdotal evidence 
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supports the irradiation of patients with stage I follicular PTL, as this treatment may be 
curative, but there are no definitive studies in the literature.  In MALT lymphomas of the 
head and neck, chemotherapy does not have a clear effect on either disease-specific or 
relapse-free survival (13). Patients with indolent histologic subtypes do require close 
long-term follow-up, as thyroid MALT may be associated with high rates of 
dissemination and recurrence (13). 
DLBCL was once treated primarily with surgical excision, but localized 
treatments now play less of a role. The rarity of this malignancy has hindered the use of 
randomized, controlled trials to study the efficacy of surgical excision in stage I disease.  
Limited radiation does enter the treatment paradigm for patients with bulky disease, as 
does the use of surgery in cases of airway obstruction.  Acute airway compromise in 
patients with DLBCL due to tumor compression or invasion of the trachea is rare, but can 
be managed with tracheostomy or with tracheal stents (30). 
Chemotherapeutic regimens 
To date, no randomized, controlled trials evaluating the efficacy of chemotherapy 
in PTL exist, but outcomes have been extrapolated from studies of extranodal non-
Hodgkin‟s lymphoma. These studies suggest that the use of chemotherapy, most 
commonly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), in patients 
with extranodal lymphomas is both well tolerated and efficacious. Most PTL patients 
who present with recurrent disease relapse at a distant site, further supporting the case for 
systemic treatment, either with chemotherapy alone or with combined modality treatment 
(31).   
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The U.S. Food and Drug Administration (FDA) approval of rituximab for the 
treatment of DLBCL has altered the chemotherapeutic approach to patients with PTL.  
Approved in 2006 for first-line treatment, rituximab is a monoclonal B-cell antibody that 
selectively binds to the CD20 antigen found on pre-B and mature B lymphocytes (32).  In 
patients with DLBCL, rituximab is approved for use with CHOP or other anthracycline-
based chemotherapy regimens. For patients with follicular lymphoma, rituximab 
improves outcomes when used in conjunction with CHOP or CVP (cyclophosphamide, 
vincristine, and prednisone) (33). 
Recently, a large study of 1222 elderly patients aged 61 to 80 years compared the 
outcomes of patients with nodal DLBCL treated with either six or eight cycles of 
rituximab and CHOP or CHOP alone.  The addition of rituximab led to significantly 
improved event-free, progression-free, and overall survival (OS) when compared with 
CHOP alone, but the additional two cycles of R-CHOP did not, suggesting that elderly 
patients are best treated with six cycles of R-CHOP (34).  As with previous advances in 
chemotherapy, treatment data from nodal lymphoma have been extrapolated to PTL, and 
many centers now treat DLBCL PTL patients with rituximab when appropriate. 
In summary, PTL is a rare malignancy, with few studies available in the literature 
that evaluate prognostic factors and significant ongoing controversy regarding optimal 
treatment paradigms for the various histologic subtypes.  This work is the first 
population-based study of PTL in the United States, and aims to provide insight into the 
demographic, clinical, and pathologic predictors of overall and disease-specific survival 
in this malignancy.  
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Statement of Purpose 
The Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute (NCI) is an excellent source for evaluating the prognosis, 
treatment and outcomes of cancer patients in the United States.  The SEER database is 
the only database of cancer patients in the U.S. that provides information on disease stage 
at diagnosis and that allows for the calculation of survival rates for each stage (35).  
Using data from the SEER database, this project will assess associations between 
demographic, clinical and pathologic characteristics of patients with primary thyroid 
lymphoma and their overall and disease-specific survival, using both bivariate and 
multivariate analyses.  To our knowledge, this work is the first population-based study of 
PTL in the U.S.  The hypotheses are as follows:  
(1) Younger age, lower stage at diagnosis, and radiation treatment will be 
independent predictors of improved survival after diagnosis of PTL.  
(2) When comparing disease-specific survival, patients with the histologic 
subtype DLBCL will have the worst disease-specific survival, and MALT will be 
associated with the best disease-specific survival. 
(3) In accordance with treatment recommendations, use of surgery in the 
treatment of PTL will have declined from 1973 to 2005, while the use of other treatment 
modalities will have increased over the same time period. 
Methods 
 Patients with PTL were identified in the Surveillance, Epidemiology, and End 
Results (SEER) database of the National Cancer Institute from 1973 to 2005. The SEER 
database was started in 1973 with 9 sites and currently provides cancer incidence and 
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survival data from 17 geographic regions (Alaska, Atlanta, greater California, 
Connecticut, Detroit, rural Georgia, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, 
New Jersey, New Mexico, San Francisco-Oakland, San Jose/Monterey, Seattle-Puget 
Sound, and Utah) representing approximately 26% of the U.S. population.  Although the 
population captured by the database is more urban than the overall population, it is 
comparable in terms of income level and education (35).   
 The International Classification of Diseases for Oncology, Third Edition (ICD-O-
3) coding system was used to select patients from SEER with primary tumors originating 
in the thyroid (ICD-O-3 code C73.9), and histology-specific codes (ICD-O-3 codes 9590-
9758) were then used to identify those with PTL. All patients with active follow-up were 
included.  Patients examined at death or by autopsy, or who were not followed after the 
diagnosis, were excluded.  
Demographic information included gender, age at diagnosis, year of diagnosis, 
geographic location, race, and marital status at diagnosis.  Age at diagnosis was analyzed 
as both a continuous and a categorical variable: age <45, 45-59, 60-69, 70-79, and ≥80.  
Year of diagnosis was analyzed with the following categories: 1973-1987, 1988-1997, 
and 1998-2005.  Geographic location was classified as West, Midwest, Northeast and 
South.  Race was categorized as white, black or other.  Marital status was categorized as 
married, single/divorced/widowed, and unknown.    
Clinical characteristics included number of other malignancies (none, 1, or ≥2) 
and systemic symptoms (asymptomatic, „„B‟‟ symptoms and/or pruritus).  Each patient‟s 
unique SEER patient identification number was used to identify other malignancies in the 
cohort of PTL patients that were also captured within the SEER database (number and 
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type of lifetime malignancies, type of prior malignancies, and radiation for prior 
malignancy).  The number of malignancies prior to the diagnosis of thyroid lymphoma 
represents the sequence of PTL in patient‟s lifetime history of malignancy, even if the 
prior malignancy is not represented in the SEER database.  Cause of death of patients 
who died during follow-up was classified as lymphoma, other malignancy, non-malignant 
medical illness, accident/injury, and other/unknown.  
Treatment modality was analyzed (no surgery or radiation, radiation only, surgery 
only, or both surgery and radiation), as was regional lymphadenectomy (none, limited, 
modified radical, or radical) and the number of regional lymph nodes examined in 
conjunction with surgery (none, 1, or >1).  Site-specific surgical therapy codes were used 
to more specifically categorize the type of operation into none (including patients 
receiving incisional, needle, or aspiration biopsy only), local excision/partial lobectomy, 
lobectomy, and near-total/total thyroidectomy.  Patients who received external beam 
radiation, with or without radioisotopes, or unspecified radiation therapy were 
categorized as a single group; patients who only received radioisotopes were categorized 
separately.  SEER does not include information regarding use of chemotherapy; 
therefore, this treatment modality could not be evaluated in our analysis.  Due to the 
limitations of the database, some clinical characteristics were analyzed over limited time 
frames.  Data for the type of operation and systemic symptoms were only available after 
1988; data for regional lymphadenectomy was available only from 1998 to 2002.   
 Pathologic characteristics examined include histologic subtype and stage at 
diagnosis.  Histologic subtype was analyzed as follows: (1) diffuse large B-cell (DLBCL) 
(ICD-O-3 9680-9684), (2) follicular (ICD-O-3 9690-9698), (3) MALT (ICD-O-3 9699), 
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(4) small lymphocytic (ICD-O-3 9670-9671), (5) Hodgkin‟s (ICD-O-3 9650-9652 and 
9663-9667), and (6) other non- Hodgkin‟s, including mixed, diffuse B-cell (ICD-O-3 
9675), mantle cell (ICD-O-3 9673), Burkitt‟s (ICD-O-3 9687), T-cell (ICD-O-3 9702-
9714), lymphoblastic (ICD-O-3 9727), and plasmacytoma (ICD-O-3 9731-9734).  
PTL is staged based on the Ann Arbor staging criteria (26).  As described in 
previous studies analyzing lymphoma using SEER (36), information on cancer stage 
according to the Ann Arbor guidelines was used to analyze PTL stage at diagnosis from 
1988 to 2005.   
Summary statistics for the entire PTL cohort and for each histologic subtype were 
obtained for all demographic, clinical, and pathologic characteristics.  Variable trends 
over time were analyzed using broad groups (1973-1987, 1988-1996, and 1997-2005) as 
well as 3 year intervals.  An analysis of variance (ANOVA) was used for continuous 
variables, and the χ
2
 test was used for categorical variables. A bivariate analysis was 
performed using the Kaplan-Meier method and log-rank test to identify significant 
prognostic factors and calculate overall and disease-specific survival. The Cox 
proportional hazards regression model was used to obtain hazard ratios for each 
independent variable and to conduct multivariate analysis. The strength of association 
between each variable and survival was reported as a hazard ratio (HR), as well as a 95% 
confidence interval (CI). Tests were 2-sided, with statistical significance assumed at a p-
value of < 0.05. The Statistical Package for Social Sciences software version 16.0 (SPSS 
Inc., Chicago, IL) was used for data analyses. SEER is a public data set that contains 
deidentified information; therefore, Institutional Review Board exemption was obtained.  
All coding of the database and statistical analyses were conducted by the author (Amanda 
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Graff-Baker), with assistance on the bivariate and multivariate analysis provided by 
Daniel Thomas, MPH. 
Results 
Summary statistics 
 A total of 1408 patients with primary thyroid lymphoma were identified over 32 
years of follow-up in the SEER database, with a median follow-up of 3.75 yrs. Seventy-
five percent of patients were female and 93% were white (Table 1).  Nearly half of the 
patients were from the West (48%), with the Midwest being the second-most represented 
region (28%).  Mean age at diagnosis was 66 years, with 24% of patients diagnosed 
between ages 60 and 69 years and 28% diagnosed between ages 70 and 79 years. Men 
were diagnosed at a younger age than women (63 vs. 68 years, respectively, p < 0.001).  
There was no significant difference in age noted when comparing patients diagnosed with 
higher and lower stage disease.      
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Table 1.  Demographic Characteristics of Patients with Primary Thyroid 
Lymphoma, SEER 1973-2005 
















  (n=1408) (n=846) (n=120) (n=123) (n=40) (n=24) 
Patient Characteristics Percent (%) 
Female 75 75 71 77 70 79 
Age  (mean years ± SD)  66.4 ±14.1 68.4 ±13.3 63.8 ±14.3 62.4 ±12.3 68.4 ±13.1 38.2 ±19.6 
     <45 7 5 8 8 2 67 
     45-59 23 20 28 31 28 21 
     60-69 24 24 24 32 20 0 
     70-79 28 31 22 24 30 8 
     >80 18 20 18 6 20 4 
Race              
     White 93 93 84 94 95 91 
     Black 1 2 0 0 0 9 
     Other 6 5 16 6 5 0 
Marital status             
     Married 58 55 63 72 67 58 
     Single/divorced 42 45 37 28 33 42 
SEER, Surveillance, Epidemiology, and End Results Program; SD, standard deviation; MALT, mucosa associated lymphoid tissue  
 
 
Histologically, 98% of patients had non-Hodgkin‟s lymphoma.  Of the entire 
cohort, 68% had DLBCL, 10% follicular, 10% MALT, 3% mixed diffuse B-cell, 3% 
small lymphocytic, 2% Hodgkin‟s, 1% plasmacytoma.  Burkitt‟s, T-cell, mantle cell, and 
lymphoblastic lymphomas each accounted for less than 1% patients.  Age at diagnosis 
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varied between histologic subtypes.  Approximately one third of patients with DLBCL 
were diagnosed between the ages of 70-79, with a mean age at diagnosis of 68.4.  The 
mean age at diagnosis for patients with MALT, follicular lymphoma and small 
lymphocytic lymphoma was also in the 60‟s.  In contrast, two-thirds of patients with 
Hodgkin‟s lymphoma were <45 years old and the mean age at diagnosis for those with 
Hodgkin‟s was 38 years, significantly younger than the mean age at diagnosis for any of 
the other histologic subtypes (p <0.001). 
Most patients (56%) had stage I disease at diagnosis (Table 2); 32% were 
diagnosed with stage II disease, 2% were diagnosed with stage III disease and 11% were 
diagnosed with stage IV disease.  Forty percent of patients underwent both surgery and 
radiation, 28% underwent surgery only, 18% were treated with radiation only, and 15% 
received neither surgery nor radiation.  70% of patients found to have stage I disease 
received surgery, compared with 60% of patients with stage II and 56% of patients with 
stage III/IV disease (p <0.001).  Older patients were less likely to receive surgery; 55% of 
patients over 80 years received surgery, while 66% of patients younger than 45 years, 
72% of patients between 45 and 59 years, 73 % of patients between 60 and 69 years, and 
67% of patients between 70 and 79 years were operated upon (p <0.001).  Operative 
treatment employed regional lymphadenectomy in only 3%.  From 1998 to 2002, the 
number of regional lymph nodes examined during surgery was recorded for 308 patients, 
with 10% having one lymph node examined, 5% having more than one, and a majority 
(85%) having no lymph nodes examined.  Patients who did not receive surgery after 1988 
overwhelming did not do so because surgery was not recommended (97%).  Radiation 
was used in 58% of patients with stage I disease, 60% of patients with stage II disease, 
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and 31% of patients with stage III/IV disease.  External beam radiation, either with or 
without additional radioactive isotopes, was used as treatment for 58% of patients.  An 
additional seven patients (0.5%) received therapy with radioactive isotopes only.   
 
Table 2.  Clinical and Pathologic Characteristics of Patients with Primary 
Thyroid Lymphoma, SEER 1973-2005 
















Patient Characteristics Percent (%) 
Surgery performed  (n=1400) (n=840) (n=119) (n=122) (n=40) (n=24) 
  68 65 83 80 80 71 
Type of Surgery (n=682) (n=406) (n=98) (n=73) (n=20) (n=9) 
     Local excision/partial     
          lobectomy 
17 19 11 11 15 11 
     Lobectomy 34 32 39 41 30 56 
     Near-total/total  
          thyroidectomy 
49 49 50 48 55 33 
Lymphadenectomy  (n=272) (n=245) (n=55) (n=31) (n=9) (n=6) 
     None 97 98 96 97 100 100 
     Limited 3 2 4 3 0 0 
     Modified radical 1 1 0 0 0 0 
     Radical 0 0 0 0 0 0 
Reason for no surgery  (n=312) (n=205) (n=18) (n=18) (n=4) (n=40) 
     Not recommended      97 97 94 100 100 75 
     Contraindicated 2 2 0 0 0 0 
     Refused 1 0 6 0 0 25 
Radiation therapy used (n=1352) (n=812) (n=117) (n=121) (n=39) (n=24) 
  59 58 55 55 56 71 
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Patient Characteristics Percent (%) 
Treatment (n=1357) (n=806) (n=116) (n=120) (n=39) (n=24) 
     No surgery or radiation 14.7 15 10 10 8 4 
     Radiation only 17.9 20 7 10 13 25 
     Surgery only 27.7 27 34 34 36 25 
     Surgery and radiation 39.7 38 48 46 44 46 
Systemic symptoms  (n=598) (n=386) (n=57) (n=53) (n=13) (n=12) 
     Asymptomatic 87 86 91 96 92 75 
     "B" symptoms and/or  
          pruritus 
13 14 9 4 8 25 
Stage  (n=1062) (n=666) (n=115) (n=91) (n=25) (n=12) 
     I 56 54 72 46 52 42 
     II 32 33 24 42 40 58 
     III 2 2 1 4 0 0 
     IV 11 12 3 8 8 0 
Died of PTL 20.5 23 4 19 13 13 
Died during follow-up 46.7 49 18 37 60 21 
SEER, Surveillance, Epidemiology, and End Results Program; SD, standard deviation; MALT, mucosa associated lymphoid tissue  
 
Patients with DLBCL were significantly less likely to receive surgery than 
patients with MALT or with follicular lymphoma (p <0.001 for both).  The percentage of 
patients undergoing radiation treatment was similar for all histologic subtypes (58.5% for 
DLBCL, 54.7% for MALT, 55.4% for follicular, and 56.4% for small lymphocytic), with 
the exception of patients with Hodgkin‟s lymphoma.  70.8% of those patients received 
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radiation.  For all histologic subtypes, patients were more likely to receive both surgery 
and radiation than they were to receive either surgery or radiation alone.   
Regardless of histologic subtype, the majority of patients presented with stage I or 
stage II disease.  Patients with MALT were less likely to present with stage III or stage 
IV disease than those with DLBCL (p <0.01) or follicular lymphoma (p <0.01).  More 
than 10% of patients with DLBCL and Hodgkin‟s presented with systemic symptoms.  
Patients with DLBCL were significantly more likely to present with systemic symptoms 
than those with follicular lymphoma (p <0.05).  Very few patients with MALT died of 
PTL (4.2%).   
For 79% of patients, PTL was their only malignancy.  Of those patients with other 
lifetime malignancies, 236 were recorded elsewhere in the SEER database.  Common 
sites of other malignancies were breast (66 patients), colon (37 patients), prostate (30 
patients), and lung (29 patients).  Of the other malignancies documented in the database, 
125 occurred prior to PTL.  29% of those patients received radiation as treatment for their 
first malignancy.   
 The use of surgery for PTL has declined over time.  81% of patients underwent 
surgery from 1973 to 1987, whereas 61% had surgery from 1997 to 2005. A similar trend 
was observed for radiation, with 69% of patients receiving radiation from 1973 to 1987, 
compared with 53% from 1997 to 2005.  Over time, PTL was diagnosed in patients at an 
earlier stage; 83% were found to have stage I or stage II disease from 1988 to 1990, 
whereas 88% were diagnosed at those stages in 2003 to 2005. 
 Of the 658 patients who died during follow-up, 44% died from lymphoma, 
whereas 35% died from a nononcologic cause.  Cardiovascular and cerebrovascular 
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disease were the most common causes of nononcologic death, accounting for 68% of 
cases. An additional 13% of patients died from non-PTL malignancies; lung cancer was 
the most common, accounting for 34% of these deaths.  Among patients who died from 
PTL, 58% succumbed within the first year after diagnosis and 88% within the first 5 
years. 
Kaplan-Meier analysis  
Median overall survival of the cohort was 9.3 years. The 5-year overall survival 
was 66% and the 5-year disease-specific survival was 79% (Fig 1).  Older age (age ≥60), 
single marital status, and more advanced stage were associated with decreased disease-
specific survival on bivariate analysis (Table 3).  When stratified by stage, patients who 
were diagnosed at a higher stage had a shorter disease-specific survival (Fig 2).  Five 
years after diagnosis, disease-specific survival was 86% for patients with stage I disease, 
81% for patients with stage II disease, and 64% for patients with stage III or IV disease. 
Receiving operative treatment or radiation was associated with improved survival. 
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Figure 1.  Overall and disease-specific survival from primary thyroid 
lymphoma.  SEER, 1973-2005. 
 
This graph displays the Kaplan-Meier survival curves from PTL for overall and disease-
specific survival.  Five-year overall survival from PTL was 66% and 5-year disease-
specific survival was 79%.  Of those who succumbed to PTL, 58% died within the first 
year.   
 
 
Table 3.  Demographic, Clinical, and Pathologic Characteristics with 
Associated Hazard Ratios Based on Bivariate Analysis of Disease-Specific 
Mortality in Patients with Primary Thyroid Lymphoma, SEER 1973-2005 
Variable 
Hazards Ratio       
(95% CI) p-value 
Gender       
     Male 1 
 
*  




Hazards Ratio       
(95% CI) p-value 
Age
A
        
     <45 1 
 
*  
     45-59 1.28 (0.59-2.76) NS 
     60-69 2.16 (1.03-4.52) <0.05 
     70-79 3.27 (1.59-6.73) 0.001 
     ≥80 6.67 (3.23-13.78) <0.001 
Marital Status
A
   
 
  
     Married 1 
 
* 
     Not married 1.83 (1.45-2.31) <0.001 
Race       
     White 1 
 
* 
     Black 1.45 (0.60-3.50) NS 
     Other 0.73 (0.40-1.34) NS 
Year of Diagnosis
A
   
 
  
     1973-1987 1 
 
* 
     1988-1996 0.71 (0.53-0.94) <0.05 
     1997-2005 0.58 (0.44-0.77) <0.001 
Treatment
A
       
     No surgery or radiation 1 
 
* 
     Radiation only 0.63 (0.43-0.93) <0.05 
     Surgery only 0.57 (0.40-0.81) <0.01 




Hazards Ratio       
(95% CI) p-value 
Type of surgery 
  
  
     None 1 
 
* 
     Local excision/partial lobectomy 0.82 (0.50-1.33) NS 
     Lobectomy 0.49 (0.32-0.77) <0.01 
     Near-total/total thyroidectomy 0.79 (0.57-1.10) NS 
Stage
A
       
     I 1 
 
* 
     II 1.41 (1.00-1.97) <0.05 
     III 1.38 (0.44-4.39) NS 
     IV 3.08 (2.12-4.47) <0.001 





     None 1 
 
* 
     1 0.60 (0.42-0.85) <0.01 
     ≥2 0.62 (0.30-1.25) NS 
Systemic symptoms       
     Asymptomatic 1 
 
* 
     "B" symptoms and/or pruritus 1.43 (0.82-2.49) NS 
Histologic Subtype
A
       
     MALT 1 
 
* 
     Diffuse large B-cell  5.46 (2.25-13.28) <0.001 
     Follicular  3.74 (1.42-9.84) <0.01 
     Small lymphocytic 2.61 (0.76-9.03) NS 
     Other non-Hodgkin‟s 3.92 (1.44-10.71) <0.01 
     Hodgkin‟s 2.43 (0.58-10.17) NS 
* reference variable; A included in multivariate analysis 
SEER, Surveillance, Epidemiology, and End Results Program; 95% CI, 95% 




Figure 2.  Disease-specific survival from primary thyroid lymphoma by 
stage.  SEER, 1988-2005 
 
Kaplan-Meier analysis was used to generate disease-specific survival curves, stratified by 
stage.  When compared to patients with stage I disease, patients with stage II and stages 
III/IV disease fared significantly less well (p <0.05 and p <0.001, respectively).   
 
 
 Older age at diagnosis was associated with shorter disease-specific survival (Fig 
3).  Disease-specific survival at 5 years was more than 90% for patients less than 60 years 
old, compared with 57% for patients ≥80 years old. There was a significant difference in 
disease-specific survival for patients whose conditions were diagnosed more than 20 
years ago compared with those from the last 2 decades (Fig 4). 
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Figure 3.  Disease-specific survival from primary thyroid lymphoma by age 
at diagnosis.  SEER, 1973-2005. 
 
Survival curves were generated based on age at diagnosis, and a relentless dose-response 
was associated with each additional ten years of age.  With age <45 as the reference, the 
decrease in survival was significant for all age brackets over 60 (p <0.05 for age 60-69, p 





Figure 4.  Disease-specific survival from primary thyroid lymphoma by year 
of diagnosis.  SEER, 1973-2005. 
 
Survival curves for year of diagnosis demonstrate a significant difference in survival for 
patients diagnosed from 1973-1987 when compared with those diagnosed from 1988-
1996 (p <0.05) and those diagnosed from 1997-2005 (p <0.001). 
 
 
 When stratified by stage, treatment with surgery and radiation or surgery alone 
was associated with improved survival for stage I disease (p < 0.001 for both), whereas 




Figure 5.  Disease-specific survival from stage I primary thyroid lymphoma 
by treatment.  SEER, 1988-2005.   
 
All three groups of patients receiving radiation or surgery had better survival than the no 
surgery or radiation group (p<0.05 for radiation only, p<0.001 for surgery only, p<0.001 
for radiation and surgery).  There was no significant difference in prognosis when 
comparing the three treatment groups.  All patients in the no surgery or radiation group 
who died from PTL did so within the first three years, so the disease-specific survival of 
that group is unchanged thereafter. 
 
 
 All variables associated with disease-specific survival were also significant for 
overall survival, with 2 exceptions. Female sex predicted worse overall survival, but it 
was not significant for disease-specific survival. The number of malignancies was only 
significant for disease-specific survival. 
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Histologic subtype analysis 
When stratified by histologic subtype, patients with DLBCL, follicular, and other 
non-Hodgkin‟s lymphomas had worse disease-specific survival than those with MALT 
lymphoma (Fig 6).  Patients with DLBCL are five times more likely to die from PTL than 
patients with MALT.  The 5-year disease-specific survival rate was 75% for DLBCL, 
87% for follicular, 86% for small lymphocytic, 83% for other non-Hodgkin‟s, and 96% 
for MALT lymphoma.  Disease-specific survival from MALT was significant when 
compared to patients with DLBCL (p <0.001), follicular lymphoma (p <0.01), and other 
non-Hodgkin‟s lymphoma (p <0.01).  Overall survival for patients with MALT was 
significantly better than for patients with DLBCL (p <0.001) and other non-Hodgkin‟s 
lymphomas (p <0.05).   
30 
 
Figure 6.  Disease-specific survival from primary thyroid lymphoma by 
histologic subtype.  SEER, 1973-2005. 
 
Kaplan-Meier survival curves for each histologic subtype demonstrate significant 
differences in survival.  Patients with MALT had the best disease-specific survival and 
were used as the reference group.  Patients with follicular lymphoma, other non-
Hodgkin‟s lymphoma, and DLBCL all had significantly worse survival (p <0.05, p <0.05, 
and p <0.001, respectively). 
 
 
For patients with DLBCL, age, marital status, treatment modality and stage at 
diagnosis were significant factors affecting disease-specific survival.  Age was also 
significant predictor of survival for patients with MALT (p =0.001) and with Hodgkin‟s 
lymphoma (p <0.001).  The hazard ratio for disease-specific survival of patients with 
DLBCL ≥ 80 years old was 5.2 when compared to patients <45 years old (p < 0.001).  
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Marriage offered some protection in terms of survival from DLBCL, with a hazard ratio 
of 1.6 for single patients (p <0.001).   
Just as in the overall analysis, DLBCL patients receiving surgery and/or radiation 
had a significantly better disease-specific survival than patients who did not receive either 
intervention.  DLBCL patients who received neither surgery nor radiation had a 5-year 
disease-specific survival of 58.7%; less than one-quarter of patients who received surgery 
and/or radiation for DLBCL had died from PTL at five years (5-year disease-specific 
survival: 79.9% for radiation only, 74.8% for surgery only, 77.4% for surgery and 
radiation).  The specific type of surgery performed for DLBCL, however, was not 
significant.   
Treatment was also a significant indicator of disease-specific survival for patients 
with follicular lymphoma.  All three groups of patients receiving treatment with surgery 
and/or radiation had hazard ratios of less than one, indicating improved survival when 
compared to patients who did not receive either treatment; however, the analysis only 
reached statistical significance for those patients who received both surgery and radiation 
(p <0.05).  Treatment was not a significant predictor of disease-specific survival on 
bivariate analysis for any of the other histologic subtypes.   
Five-year disease specific survival decreased with increased stage for patients 
with DLBCL, MALT, follicular lymphoma, and other non-Hodgkin‟s lymphoma; these 
decreases reached statistical significance only for DLBCL and MALT (Table 4).  For 
patients with DLBCL, only one in five patients diagnosed with stage I disease will 
succumb within five years, whereas 40% of patients with stage III or stage IV disease 
will die from PTL during that time.   
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Table 4.  Five-Year Disease-Specific Survival by Histologic Subtype and 
Stage in Patients with Primary Thyroid Lymphoma, SEER 1988-2005 
Histologic subtype Disease-specific 
survival (SE) 
p-value 
Diffuse large B-cell  
 
  
     Stage I (n=357) 81.7% (2.3%) * 
     Stage II (n=217) 75.8% (3.3%) NS 
     Stage III/IV (n=92) 60.4% (5.6%) <0.001 
Follicular      
     Stage I (n=42) 94.3 % (3.9%) * 
     Stage II (n=38) 91.0% (5.0%) NS 




     Stage I (n=83) 97.5% (1.7%) * 
     Stage II (n=28) 95.8% (4.1%) NS 
     Stage III/IV (n=4) 50.0% (35.4%) <0.05 
Small lymphocytic     
     Stage I (n=13) 82.1% (11.7%) * 
     Stage II (n=10) 100% NS 




     Stage I (n=32) 93.8% (4.3%) * 
     Stage II (n=16) 92.3% (7.4%) NS 
     Stage III/IV (n=8) 85.7% (13.2%) NS 
Hodgkin’s     
     Stage I (n=5) 75.0% (21.7%) * 
     Stage II (n=7) 100% NS 
     Stage III/IV (n=0)  -- NS 
* reference variable 
SEER, Surveillance, Epidemiology, and End Results Program; SE, 




When disease-specific survival for each histologic subtype was assessed based on 
stage and treatment modality, treatment with surgery and/or radiation were associated 
with improved survival for patients with stage I DLBCL, small lymphocytic, and MALT 
histologies. Stage II DLBCL treated with radiation had a better prognosis than stage II 
DLBCL treated with neither surgery nor radiation (p < 0.05); treatment of stage II 
DLBCL with surgery, either with or without radiation, was not associated with improved 
prognosis.  There were no other significant associations between histologic subtype and 
treatment modality for stages II, III, and IV. 
Multivariate analysis 
 Age, treatment modality, PTL stage, and histologic subtype remained significant 
predictors of disease-specific survival in multivariate analysis (Table 5). Age ≥80 
remained an independent predictor of decreased survival (p <0.001). Patients with stage 
IV disease were 2.2 times more likely to die than those with stage I (p <0.001). All 
treatment groups did better than the no surgery or radiation group. Compared with 
patients with MALT lymphoma, patients with DLBCL were nearly 5 times more likely to 





Table 5.  Demographic, Clinical, and Pathologic Characteristics with 
Associated Hazards Ratios Based on Multivariate Analysis of Disease-
Specific Mortality in Patients with Primary Thyroid Lymphoma, SEER 
1988-2005 









     <45 1 
 
* 
     46-59 0.65 (0.24-1.76) NS 
     60-69 1.03 (0.41-2.63) NS 
     70-79 2.18 (0.91-5.25) NS 
     ≥80 4.57 (1.91-10.96) 0.001 
Treatment       
     No surgery or radiation 1 
 
* 
     Radiation only 0.43 (0.26-0.73) <0.01 
     Surgery only 0.59 (0.38-0.92) <0.05 




     I 1 
 
* 
     II 1.35 (0.94-1.95) NS 
     III 1.76 (0.55-5.71) NS 
     IV 2.19 (1.44-3.34) <0.001 
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Histologic Subtype       
     MALT 1 
 
* 
     Diffuse large B-cell  4.87 (1.79-13.26) <0.01 
     Follicular  3.55 (1.15-10.96) <0.05 
     Small lymphocytic 1.78 (0.33-9.73) NS 
     Other non-Hodgkin‟s 1.89 (0.50-7.12) NS 
     Hodgkin‟s 3.89 (0.40-37.71) NS 
* reference variable 
SEER, Surveillance, Epidemiology, and End Results Program; 95% CI, 95% 
confidence interval;  NS, not significant; MALT, mucosa associated lymphoid tissue  
 
Discussion 
PTL is a rare malignancy, with an estimated annual incidence similar to that of 
anaplastic thyroid cancer (3).  To our knowledge, this study represents the first 
population-level analysis of patients with this disease.  PTL most commonly affects white 
women over 60 years old, and most patients are found to have stage I disease.  DLBCL is 
the most common histology and it carries the worst prognosis.  The use of surgery and 
radiation for PTL has declined over time, although a majority of patients continue to 
receive both surgery and radiation.  PTL is more likely to be diagnosed at an earlier stage 
now than it was 20 years ago.  Approximately half of the patients died within 10 years of 
diagnosis, but less than half of those died from PTL.  In our multivariate analysis, age 
≥80 years, advanced PTL stage, lack of radiation or surgical treatment, and DLBCL and 




 To date, published analyses of PTL have been limited by small sample size, 
leading to discrepancies in the reported prevalence of histologic subtypes, overall and 
disease-specific survival, and significant prognostic indicators.  Prior to this analysis, the 
largest study of PTL in the United States analyzed 108 cases (5).  In that study, 66% of 
patients presented with stage I disease.  Most patients had DLBCL, whereas 
approximately one third of patients were found to have MALT lymphoma. Stage, but not 
treatment, was associated with survival; no patients with stage I disease died during 
follow-up. No significant differences in survival were found for stages II, III, or IV. 
 A literature review that included 211 patients concluded that combined 
chemoradiation therapy should be the mainstay of treatment for PTL (37).  Patients 
treated with both radiation and chemotherapy had significantly lower rates of distant and 
overall recurrence compared with those who received only one treatment modality. This 
analysis was limited to radiation and chemotherapy and did not include operative 
treatment. A more recent analysis of 50 PTL patients by Meyer-Rochow et al. (29) found 
that 54% of patients presented with stage II disease, with significant differences in 
survival between stages.  No difference in disease-free survival was found when patients 
underwent resection versus open biopsy, leading the authors to conclude that surgery 
should be employed only to establish the diagnosis of PTL or to manage severe airway 
obstruction. 
 Overall, the demographic characteristics of our large cohort were similar to those 
described in smaller, single-institution series (5, 9, 17, 18, 29, 38-42).  Our study is the 
first to show a significant disparity between the sexes in the mean age at diagnosis, with 
men diagnosed at a younger age.  However, there was no significant difference between 
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the sexes with regard to disease-specific survival.  Prior studies have found that 
approximately 90% of patients are found to have early stage PTL (5, 18, 29, 38).  This is 
consistent with the current study.  The distribution of patients between stage I and stage II 
varies widely in the literature, ranging from 31% to 71% for stage I (5, 18, 29, 38-41, 43, 
44).  Our finding of 56% of patients with stage I disease is within the reported range. 
There is consensus that DLBCL is the most common histologic subtype (3, 4, 45, 46); in 
our study, DLBCL accounted for 68% of all PTL.  There is no such consensus about the 
incidence of less common histologies. MALT lymphoma is thought to be the second-
most common histology in PTL; most studies have reported rates of 20% to 40% (5, 9, 
42)  Only 10% of our cohort had MALT and a larger percentage had follicular lymphoma 
that has been reported in most studies (5, 18, 42).  
 Reported overall survival from PTL ranges from 56% to 90% (9, 31).  Derringer 
et al. (5) reported a 5-year disease-specific survival of 79%, with 90% of deaths occurring 
within the first three years after diagnosis.  Our findings are similar, with a 5-year 
disease-specific survival of 79% and 80% of deaths occurring within the first 3 years. 
While 5-year disease-specific survival for stage I has been reported to be as high as 100% 
(5, 39), other studies have not found that stage I patients do so well (6, 31); in the current 
study, 14% of patients with stage I PTL died within 5 years of their diagnosis. 
 Belal et al. (39) reported that age had no effect on overall or recurrence-free 
survival; in contrast, DiBiase et al. (31) found that advanced age was associated with 
shorter overall survival.  In the current study, a dose-response association was observed 
between increasing age and shorter disease-specific survival.  Older age was associated 
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with more aggressive histology; still, age remained an independent predictor of disease-
specific survival after adjustment for histology in our multivariate analysis.   
Several studies have concluded that PTL stage and histology predict prognosis; 
that is, patients examined at an earlier stage or with MALT lymphoma have the best 
outcomes (5, 18, 29).  These studies have relied on bivariate comparisons, rather than 
multivariate analysis, to provide support for these conclusions, as none of the series have 
been large enough to power a multivariate analysis.  Studies that report significant 
survival differences based on stage have concluded that patients with stage I disease fare 
significantly better than those with stage IV (5, 6, 29); there is less consensus about 
prognostic implications of stage II and stage III disease.  Our multivariate analysis 
indicated that patients with stage IV disease were twice as likely to die from PTL as those 
with stage I disease, but found no significant differences in survival of patients with stage 
I disease when compared to those with stage II or stage III disease.  
Despite concluding that histologic subtype is an important factor in disease-
specific survival from PTL, few studies have been large enough to conduct statistical 
analysis comparing the different histologic subtypes or to assess prognostic factors for 
each histologic subtype.  This is the first study encompassing a large enough number of 
patients with PTL to allow for such analysis.  We found that patients with DLBCL and 
follicular lymphoma were more likely to present with advanced stage disease than those 
with MALT.  Patients with DLBCL were more likely to present with systemic symptoms 
than those with follicular lymphoma.  The bivariate analyses  conducted for each 
histologic subtype were most robust for DLBCL, where age, marital status, treatment and 
stage were all found to be significantly associated with disease-specific survival from 
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DLBCL.  Disease-specific survival for patients with DLBCL and follicular lymphoma 
was significantly worse when compared with MALT lymphoma in multivariate analysis, 
thus corroborating prognostic value of histologic subtype for PTL. 
 In our multivariate analysis, the year of diagnosis was not associated with 
survival, which indicated that patients whose conditions were diagnosed in 2005 did not 
fare better than those whose conditions were diagnosed in 1988, despite considerable 
changes in the treatment paradigm for PTL during the last 2 decades. Treatment analysis 
in SEER was limited by a lack of chemotherapy data and by our inability to extrapolate 
surgical intent from the database. Still, several treatment-related results were available. 
Despite a growing consensus over the last decade that PTL is best treated by 
chemotherapy and/or radiation, depending on the histologic subtype (29, 37, 45), 61% of 
patients underwent surgery for PTL from 1997 to 2005. Possible reasons for surgical 
resection include tumor debulking for advanced disease, definitive treatment for stage I, 
or inappropriate operations. It is also possible that some patients underwent surgery for 
other thyroid pathology, and the diagnosis of PTL was only appreciated in the 
postoperative setting.  Procedures used for the diagnosis of PTL and acquisition of tissue 
for immunohistochemical studies prior to the enrollment in chemotherapeutic protocols, 
such as incisional, needle, and aspiration biopsies, were not considered surgical 
procedures in our analysis, thus eliminating the possibility that high rates of surgery seen 
from 1997 to 2005 were a reflection of increased diagnostic testing. 
 There are no published randomized, controlled trials studying the efficacy of 
chemotherapy for PTL; therefore, chemotherapy regimens have been extrapolated from 
studies of extranodal lymphomas (45).  Approved by the FDA after the conclusion of the 
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study period in 2006 as a first-line therapy for non-Hodgkin‟s lymphoma, rituximab has 
been used for off-label treatment of non-Hodgkin‟s PTL for the last several years.  We 
were unable to assess whether any patients captured in the SEER database were treated 
with rituximab off-label.  Patients with DLBCL at most centers receive 6-8 courses of R-
CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) as 
an initial treatment (18, 45).  A single case report exists describing the treatment of PTL 
with rituximab. This patient was diagnosed with stage IE DLBCL in the left thyroid lobe 
after having a right lobectomy 10 years prior for medullary thyroid carcinoma. Treated 
with six courses of R-CHOP, the thyroid mass completely disappeared, and the patient 
achieved complete remission for the 34 months of follow-up (47). 
 Controversy still exists about the role of thyroid surgery for early stage disease (3, 
4, 37, 44, 45).  Our results suggest that surgery and radiation are associated with 
improved disease-specific survival for patients with stage I PTL.  A study of 62 patients 
from the Mayo Clinic concluded that thyroidectomy with adjuvant chemotherapy 
provided long-term cure for PTL contained within the thyroid capsule (48).  Other studies 
provide retrospective evidence for the use of single-modality therapy with surgery or 
radiation for indolent forms of PTL such as MALT (5, 45).  Our data supported an 
association between surgery and/or radiation and the improved survival for patients with 
stage I MALT, DLBCL, and small lymphocytic histologies. The recurrence rates for PTL 
have been shown to be reduced by chemotherapy, but we could not test this finding in 
SEER. 
 Limitations of this study include those inherent to any analysis using a large 
database, such as coding errors, although SEER has been well validated. SEER does not 
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include imaging or central pathologic review. Information regarding chemotherapy is not 
available; therefore, the decline in use of surgery and radiation and the rise in the 
percentage of patients receiving neither surgery nor radiation over time might reflect 
increasing use of chemotherapy. SEER does not include information about patient 
comorbidities, so the number of primary tumors was the only available proxy for patient 
(oncologic) comorbidity.  SEER also does not include recurrence or reoperation rates, so 
measurable outcomes were limited to overall and disease-specific survival. 
 In conclusion, this represents the largest population-based study of PTL published 
to date. Patient age, PTL stage and histology, and treatment modality are independently 
associated with survival.  The paucity of data from large studies adequately powered to 
examine a relatively rare clinical entity such as PTL implies the need for additional 
research. We propose the creation of a retrospective/prospective multi-institutional 
thyroid lymphoma database that incorporates centers with experience in oncology, 
endocrinology, and thyroid surgery. In particular, future study should be committed to 
examining the role of operative treatment for early stage PTL. Given the importance of 
early diagnosis for improved survival, education of the public as well as of primary care 
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